Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Japan Tobacco Inc.    2914   JP3726800000

JAPAN TOBACCO INC.

(2914)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Japan Tobacco : Listing on the Japanese National Health Insurance Drug Price List and Launch of ENAROY® Tablets 2 mg・4 mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan

11/18/2020 | 01:07am EST

FOR IMMEDIATE RELEASE

Tokyo, November 18, 2020

Listing on the Japanese National Health Insurance Drug Price List and

Launch of ENAROY® Tablets 2 mg4 mg

for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan

Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announced that ENAROY® Tablets 2 mg and 4 mg (generic name: enarodustat) (hereinafter "ENAROY®"), a hypoxia inducible factor prolyl hydroxylase (HIF-PH) inhibitor, have been listed on the Japanese National Health Insurance (NHI) drug price list as of today. On September 25, 2020, JT received manufacturing and marketing approval of ENAROY® in Japan for an indication of anemia associated with chronic kidney disease (CKD) . Torii plans to launch ENAROY® in Japan on December 8, 2020.

ENAROY® is an orally-activeHIF-PH inhibitor that promotes erythropoiesis by accelerating the endogenous production of erythropoietin (EPO) and controlling the expression of molecules responsible for iron metabolism. The Phase 3 clinical studies confirmed the efficacy and safety of ENAROY® in anemic patients with CKD, including non-dialysis patients and those receiving peritoneal dialysis or hemodialysis.

JT and Torii expect ENAROY® to be a new option for the treatment of anemia associated with CKD in Japan.

ENAROY® Tablets 2 mg4 mg

Product Name:

ENAROY® Tablets 2 mg4 mg

Generic Name:

Enarodustat

Indications:

Anemia associated with CKD

Package:

ENAROY® Tablets 2 mg

140 tablets (14 tablets (PPT) × 10 )

ENAROY® Tablets 4 mg

140 tablets (14 tablets (PPT) × 10 )

Dosage and

For non-dialysis CKD patients and peritoneal dialysis

Administration:

patients;

The recommended starting dose for adult patients

is 2 mg taken orally once daily before a meal or at

bedtime. Thereafter, the dose should be adjusted

as appropriate depending on the patient's

condition. The maximum dose is 8 mg per dose.

For hemodialysis patients;

The recommended starting dose for adult patients

is 4 mg taken orally once daily before a meal or at

bedtime. Thereafter, the dose should be adjusted

as appropriate depending on the patient's

condition. The maximum dose is 8 mg per dose.

NHI Drug Price:

ENAROY® Tablets 2 mg¥ 275.90 per tablet

ENAROY® Tablets 4 mg¥ 486.10 per tablet

Approval Date:

September 25, 2020

NHI Pricing Date:

November 18, 2020

Launch Date:

December 8 , 2020

Manufacturing and

Japan Tobacco Inc.

Distributor:

Distributor:

Torii Pharmaceutical Co., Ltd.

ABOUT Anemia Associated with CKD

Anemia is one of the complications in CKD patients. The major cause of anemia in patients with CKD is considered to be a decreased ability to produce EPO in the kidney associated with renal dysfunction. Insufficient oxygen supply due to decreased erythrocyte counts associated with anemia decreases the energy production in organs and induces reduction in mobility and activities in daily life, which leads to a poor quality of life.

###

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With approximately 62,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its tobacco vapor products under its Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit https://www.jt.com/.

Contact for Japan Tobacco Inc.:

Dinesh Babu Thotakura, General Manager

Media and Investor Relations Division

Japan Tobacco Inc.

Tokyo: +81-3-6636-2026

E-mail: jt.media.relations@jt.com

Contact for Torii Pharmaceutical Co., Ltd.:Corporate Planning Department (Public Relations)

Torii Pharmaceutical Co., Ltd. Tokyo: +81-3-3231-6814E-mail:webmaster@torii.co.jp

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Japan Tobacco Inc. published this content on 18 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 November 2020 06:06:03 UTC


© Publicnow 2020
All news about JAPAN TOBACCO INC.
01/13JAPAN TOBACCO : Furthers Sales Reach for Tobacco-Infused Vapor Device
MT
01/13JAPAN TOBACCO : JT expands “Ploom TECH+ with” sales area nationwide ..
PU
2020JAPAN TOBACCO INC. : Ex-dividend day for final dividend
FA
2020British American Tobacco boosts revenue outlook for 2020
RE
2020JAPAN TOBACCO : JT Group Recognized on CDP's “Climate A List” and &l..
PU
2020Big Tobacco gets a pandemic pick-me-up
RE
2020JAPAN TOBACCO INC. : - Listing on the Japanese National Health Insurance Drug Pr..
AQ
2020Japan Tobacco, Torii's ENAROY Tablets Land on Japanese National Health Insura..
MT
2020JAPAN TOBACCO : Listing on the Japanese National Health Insurance Drug Price Lis..
PU
2020Japan Tobacco's Profit Slides on Lower Revenues in January-September Period
MT
More news
Financials
Sales 2020 2 084 B 20 057 M 20 057 M
Net income 2020 306 B 2 946 M 2 946 M
Net Debt 2020 546 B 5 258 M 5 258 M
P/E ratio 2020 11,9x
Yield 2020 7,49%
Capitalization 3 653 B 35 195 M 35 158 M
EV / Sales 2020 2,02x
EV / Sales 2021 1,92x
Nbr of Employees 61 975
Free-Float 55,2%
Chart JAPAN TOBACCO INC.
Duration : Period :
Japan Tobacco Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAPAN TOBACCO INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 2 387,53 JPY
Last Close Price 2 059,00 JPY
Spread / Highest target 50,6%
Spread / Average Target 16,0%
Spread / Lowest Target -9,66%
EPS Revisions
Managers and Directors
NameTitle
Masamichi Terabatake President, CEO & Representative Director
Yasutake Tango Chairman
Naohiro Minami CFO, Representative Director & Executive VP
Hiroyuki Miki Executive Officer, Head-Research & Development
Mutsuo Iwai Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
JAPAN TOBACCO INC.-2.05%35 195
ALTRIA GROUP, INC.0.49%76 567
ITC LIMITED4.23%36 650
PT HANJAYA MANDALA SAMPOERNA TBK-2.99%12 070
KT&G CORPORATION-1.68%9 193
PT GUDANG GARAM TBK-0.49%5 579